Skip Navigation


European Heart Journal Advance Access originally published online on May 11, 2005
European Heart Journal 2005 26(19):2007-2012; doi:10.1093/eurheartj/ehi312
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/19/2007    most recent
ehi312v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Straus, S. M.J.M.
Right arrow Articles by Stricker, B. H.Ch.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Straus, S. M.J.M.
Right arrow Articles by Stricker, B. H.Ch.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death

Sabine M.J.M. Straus1,2,3, Miriam C.J.M. Sturkenboom1,2, Gysèle S. Bleumink1,4, Jeanne P. Dieleman1,2, Johan van der Lei2, Pieter A. de Graeff3,5, Jan Herre Kingma4,5 and Bruno H.Ch. Stricker1,4,*

1Pharmaco-Epidemiology Unit, Departments of Epidemiology and Biostatistics and Internal Medicine, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands
2Department of Medical Informatics, Erasmus Medical Center, 3000 DR Rotterdam, The Netherlands
3Medicines Evaluation Board, The Hague, The Netherlands
4Inspectorate for Health Care, The Hague, The Netherlands
5Department of Clinical Pharmacology, University of Groningen, Groningen, The Netherlands

Received 6 February 2005; revised 1 April 2005; accepted 7 April 2005; online publish-ahead-of-print 11 May 2005.

* Corresponding author. Tel: +31 10 4088229. E-mail address: b.stricker{at}erasmusmc.nl

Aims To assess the association between the use of non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.

Methods and results A population-based case–control study was performed in the Integrated Primary Care Information (IPCI) project, a longitudinal observational database with complete medical records from more than 500 000 persons. All deaths between 1 January 1995 and 1 September 2003 were reviewed. Sudden cardiac death was classified based on the time between onset of cardiovascular symptoms and death. For each case, up to 10 random controls were matched for age, gender, date of sudden death, and general practice. The exposure of interest was the use of non-cardiac QTc-prolonging drugs. Exposure at the index date was categorized into three mutually exclusive groups of current use, past use, and non-use. The study population comprised 775 cases of sudden cardiac death and 6297 matched controls. Current use of any non-cardiac QTc-prolonging drug was associated with a significantly increased risk of sudden cardiac death (adjusted OR: 2.7; 95% CI: 1.6–4.7). The risk of death was highest in women and in recent starters.

Conclusion The use of non-cardiac QTc-prolonging drugs in a general population is associated with an increased risk of sudden cardiac death.

Key Words: Sudden cardiac death • Non-cardiac QTc-prolonging drugs • Pharmaco-epidemiology • Population based


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
C. Newton-Cheh, C.-Y. Guo, M. G. Larson, S. L. Musone, A. Surti, A. L. Camargo, J. A. Drake, E. J. Benjamin, D. Levy, R. B. D'Agostino Sr, et al.
Common Genetic Variation in KCNH2 Is Associated With QT Interval Duration: The Framingham Heart Study
Circulation, September 4, 2007; 116(10): 1128 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 EuropaceHome page
B. Darpo
Detection and reporting of drug-induced proarrhythmias: room for improvement
Europace, September 1, 2007; 9(suppl_4): iv23 - iv36.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. L. Strevel, D. J. Ing, and L. L. Siu
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. S. Gill, S. E. Bronskill, S.-L. T. Normand, G. M. Anderson, K. Sykora, K. Lam, C. M. Bell, P. E. Lee, H. D. Fischer, N. Herrmann, et al.
Antipsychotic Drug Use and Mortality in Older Adults with Dementia
Ann Intern Med, June 5, 2007; 146(11): 775 - 786.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
I. Gussak and H. M. Gussak
Sudden cardiac death in nephrology: focus on acquired long QT syndrome
Nephrol. Dial. Transplant., January 1, 2007; 22(1): 12 - 14.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. E. Bates, D. R. Rosing, T. Fojo, and R. L. Piekarz
Challenges of Evaluating the Cardiac Effects of Anticancer Agents.
Clin. Cancer Res., July 1, 2006; 12(13): 3871 - 3874.
[Full Text] [PDF]

Home page
 Journal Watch CardiologyHome page
Risk from Noncardiac QTc-Prolonging Drugs
Journal Watch Cardiology, September 30, 2005; 2005(930): 4 - 4.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.